

Professor Joel Tarning

Professor Joel Tarning received his PhD from Goteborg University, Sweden in 2007 and started his scientific research career the same year at the Mahidol-Oxford Tropical Medicine Research Unit (MORU) in Bangkok, Thailand. In 2013, he took on the responsibility as Head of the Department of Clinical Pharmacology at MORU and has been leading the pharmacology department since. He was conferred the title Professor of Clinical Pharmacology at the University of Oxford, UK in 2016, less than 9 years after completing his PhD. Professor Tarning is also a visiting professor at the Faculty of Tropical Medicine, Mahidol University, Thailand since 2016.



Professor Tarning leads a large and diverse team of 30 people studying clinical pharmacology and the main scientific directions within the department are Pharmacometric data analysis, Bioanalytical method development, Drug quantification of clinical study samples, and Omics-based research.

His main research is focused on antimalarial dose-optimisation in vulnerable populations at risk of treatment failure and resistance development, such as children and pregnant women. His work on population pharmacokinetic-pharmacodynamic modelling of oral dihydroartemisinin-piperaquine in children with uncomplicated malaria, and intramuscular artesunate in children with severe malaria started the debate on new dose recommendations in young children, which resulted in revised WHO Guidelines for the treatment of malaria, 3rd edition (2015).

Professor Tarning has published over 120 peer-reviewed articles in international journals, mostly focusing on the clinical pharmacology of antimalarial drugs. Among these articles are numerous high-impact papers in journals such as *New England Journal of Medicine*, *Lancet Infectious Diseases* and *PLOS Medicine*, resulting in a total of 6,606 citations. He is a member of the editorial board for four journals, including *CPT: Pharmacometrics & Systems and Antimicrobial Agents and Chemotherapy*. He has reviewed articles for over 30 different journals and is frequently acting as an expert reviewer on grant proposals for the Medical Research Councils in UK and Sweden, and the Wellcome Trust.

Professor Tarning has been an external expert for the World Health Organisation on several different review groups since 2008, and was part of writing the latest edition of the antimalarial dosing guidelines (2015). His work on clinical pharmacology of antimalarial drugs have already made a large impact on public health and he was awarded the biennial Giorgio Segré Prize from the European Federation for Pharmaceutical Sciences in 2014 for his research.